tradmap

ABOS Earnings Acumen Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$5 -$3 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$121M -$61M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-172% -66% 39% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
EPS
Net income (quarterly)
-$41M -$20M $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Net income
Return on equity (quarterly)
-73% -37% 0% Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
ROE

Reported EPS history

1–26 of 26
Q3 20262026-09-30-0.352026-10-2610-Q
Q2 20262026-06-30-0.452026-08-1210-Q
Q1 20262026-03-31-0.332026-05-1210-Q
Q4 2025 (derived)2025-12-31-0.402026-03-2610-K
FY 20252025-12-31-2.002026-03-2610-K
Q3 20252025-09-30-0.442025-11-1210-Q
Q2 20252025-06-30-0.682025-08-1210-Q
Q1 20252025-03-31-0.482025-05-1310-Q
Q4 2024 (derived)2024-12-31-0.622025-03-2710-K
FY 20242024-12-31-1.712025-03-2710-K
Q3 20242024-09-30-0.502024-11-1210-Q
Q2 20242024-06-30-0.342024-08-1310-Q
Q1 20242024-03-31-0.252024-05-1410-Q
Q4 2023 (derived)2023-12-31-0.282024-03-2610-K
FY 20232023-12-31-1.082024-03-2610-K
Q3 20232023-09-30-0.242023-11-1310-Q
Q2 20232023-06-30-0.282023-08-0810-Q
Q1 20232023-03-31-0.282023-05-0910-Q
Q4 2022 (derived)2022-12-31-0.322023-03-2710-K
FY 20222022-12-31-1.062023-03-2710-K
Q3 20222022-09-30-0.262022-11-1410-Q
Q2 20222022-06-30-0.252022-08-1510-Q
Q1 20222022-03-31-0.23——
FY 20212021-12-31-5.02——
Q3 20212021-09-30-0.10——
Q2 20212021-06-30-141.93——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.